This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 5mg | $90 | 3-6 Days |
| 10mg | $135 | 3-6 Days |
| 25mg | $210 | 3-6 Days |
| 50mg | $350 | 3-6 Days |
| 100mg | $550 | 3-6 Days |
| 250mg | $950 | 3-6 Days |
| 500mg | $1550 | 3-6 Days |
: Cat #: V3555 CAS #: 1394854-52-4 Purity ≥ 98%
Description: GSK-J2 is the isomer of GSK-J1 without any specific activity. GSKJ1 (GSK-J1) is a novel, highly selective and potent inhibitor of histone demethylase H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A. It that has significant activity (IC50 60 nM for human JmjD3) in vitro and in cell assays using an ester prodrug derivative (GSK-J4: 1 µM < IC50 < 10 µM; e.g. 9 µM in primary human macrophages). The KDM5/JARID1 family of Fe(II)- and α-ketoglutarate-dependent demethylases remove methyl groups from tri- and dimethylated lysine 4 of histone H3. Accumulating evidence from primary tumors and model systems supports a role for KDM5A (JARID1A/RBP2) and KDM5B (JARID1B/PLU1) as oncogenic drivers. The pyridine regio-isomer GSK-J2 displays significantly less on-target activity (IC50 > 100 µM for human JmjD3) and thus can be used as control for target effects in vitro, and as ester derivative (GSK-J5) in cells. Recent data has shown that GSK-J1 also shows some activity (IC50 950 nM for Jarid1b, IC50 1.76 uM for Jarid1c) against H3K4me3/2/1 demethylases.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 389.45 |
|---|---|
| Molecular Formula | C22H23N5O2 |
| CAS No. | 1394854-52-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: >40 mg/mL |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Synonyms | GSKJ2; GSKJ 2; GSKJ-2 |
| Protocol | In Vitro | In vitro activity: In HEK-293 cells, GSK-J1 inhibits the activities of transiently transfected JMJD3 and UTX. GSK-J1 also inhibits TNF-α production by human primary macrophages by increasing total nuclear H3K27me3 levels. In MC3T3-E1 cells, GSK-J1 suppresses Runx2 and Osterix expressions and ALP activity, and increases the global levels of H3K27me3. Kinase Assay: purified JmjD3 (1 μM) and UTX (3 μM) is incubated with 10 μM peptide [BiotinKAPRKQLATKAARK(me3 )SAPATGG] in 50 mM HEPES pH 7.5, 150 mM KCl, 50 μM (NH4)2SO4·FeSO4·H2O, 1 mM 2-oxoglutarate, and 2 mM ascorbate (JmjD3, 3 minutes at 25°C; UTX, 20 minutes at 25°C) with various concentration of the inhibitor (0, 0.005, 0.01, 0.02, 0.05, 0.1 μM). 10 mM EDTA is added to stop the reaction. The reaction is desalted by zip tip and spotted on a MALDI plate with α-cyano-4-hydroxycinnamic acid MALDI matrix. Samples are analysed on a MALDI-TOF R system. Cell Assay: Interestingly, the relative selectivity of JIB-04 toward KDM5B over KDM5C in vitro translates to a ~10-50-fold greater growth-inhibitory activity against breast cancer cell lines. |
|---|---|---|
| In Vivo | GSK J4 showed significant growth-inhibitory activity against SF8628 subcutaneous tumors. | |
| Animal model | Mice harboring subcutaneous SF8628 K27M xenografts |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.5677 mL | 12.8386 mL | 25.6772 mL | 51.3545 mL |
| 5mM | 0.5135 mL | 2.5677 mL | 5.1354 mL | 10.2709 mL |
| 10mM | 0.2568 mL | 1.2839 mL | 2.5677 mL | 5.1354 mL |
| 20mM | 0.1284 mL | 0.6419 mL | 1.2839 mL | 2.5677 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.